Vor Biopharma Inc. VOR
18.52 USD +0.69 (+3.87%)
Regular-session close
18.52 0.00 0.00%
After hours · Nov 19, 4:01 PM ET
17.71 Day range 19.13
6.50 52-week range 26.00
- YTD
- +41.59%
- 1 year
- +136.83%
News
globenewswire.com Vor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise RemeGen's expertise and next generation engineering expand Vor Bio's leadership in the BAFF/APRIL field RC298 is a next generation, long-acting dual BAFF/APRIL inhibitor designed to combine high…benzinga.com Vor Bio Announces Final Two-Year Results From Phase 3 TELIGAN Trial Evaluating Telitacicept In Adults With Iga Nephropathy; TELIGAN Met Stage B Primary Endpoint Annualized eGFR slope of -0.6 vs. -5.7 mL/min/1.73 m²/year for placebo, a 5.1 mL/min/1.73 m²/year treatment difference (p<0.001)89% and 81% reductions in risk of confirmed ≥30% and ≥40% eGFR declines,
